{"id":"endocrine-modulating-drug-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4303269","moleculeType":"Small molecule","molecularWeight":"389.86"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This type of therapy involves altering the body's hormonal balance to achieve therapeutic effects. By modulating the endocrine system, endocrine-modulating drug therapy can help regulate various bodily functions and treat conditions such as hormone-related cancers.","oneSentence":"Endocrine-modulating drug therapy works by modulating the body's endocrine system to treat various conditions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:50.918Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive breast cancer"}]},"trialDetails":[{"nctId":"NCT02597426","phase":"","title":"Nasopharyngeal Carcinoma Post IMRT","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2015-06","conditions":"Nasopharyngeal Carcinoma","enrollment":108},{"nctId":"NCT06810765","phase":"PHASE2","title":"Trifecta Research Study","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2025-09","conditions":"PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma","enrollment":""},{"nctId":"NCT04915508","phase":"PHASE2","title":"Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-06-23","conditions":"Prostate Adenocarcinoma, Stage IIIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIIC Prostate Cancer AJCC v8","enrollment":102},{"nctId":"NCT03369067","phase":"NA","title":"Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2017-12-18","conditions":"Type 1 Diabetes Mellitus","enrollment":48},{"nctId":"NCT05340634","phase":"PHASE4","title":"Evaluation of Metionac for the Modulation of Metabolic and Endocrine Parameters in Patients With PCOS.","status":"COMPLETED","sponsor":"Margan Biotech","startDate":"2020-04-20","conditions":"Polycystic Ovary Syndrome","enrollment":90},{"nctId":"NCT01215578","phase":"PHASE2","title":"Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-10","conditions":"Neuroendocrine Tumors, Pancreatic Neoplasms, Advanced Disease","enrollment":33},{"nctId":"NCT00003394","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1998-04","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT00929591","phase":"PHASE3","title":"SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1989-05","conditions":"Breast Cancer","enrollment":1558},{"nctId":"NCT00003343","phase":"PHASE3","title":"Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"1998-03","conditions":"Prostate Cancer","enrollment":525},{"nctId":"NCT00003080","phase":"PHASE1","title":"Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1996-09","conditions":"Ovarian Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"endocrine-modulating drug therapy","genericName":"endocrine-modulating drug therapy","companyName":"Fred Hutchinson Cancer Center","companyId":"fred-hutchinson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Endocrine-modulating drug therapy works by modulating the body's endocrine system to treat various conditions. Used for Hormone receptor-positive breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}